Summary of Myanmar clinical practice guidelines on the management of Dyslipidaemia in Type 2 Diabetes Mellitus
- Author:
Tint Swe Latt
1
;
Than Than Aye
2
;
Ko Ko
2
;
Aung Cho Myint
3
;
Ye Myint
4
Author Information
- Publication Type:Journal Article
- Keywords: Dyslipidaemia; Clinical practice guidelines
- MeSH: Myanmar; Practice Guideline
- From: Journal of the ASEAN Federation of Endocrine Societies 2014;29(2):112-115
- CountryPhilippines
- Language:English
- Abstract: Cardiovascular disease is a significant cause of morbidity and mortality in patients with diabetes mellitus (DM). According to the IDF Diabetes Atlas 2013, the prevalence of diabetes in Myanmar is 5.7%.(1) Diabetes is recognized as a risk equivalent for coronary heart disease. The lipid profile in patients with type 2 DM is characterized by elevated triglycerides, low high-density lipoprotein cholesterol and raised small dense low-density lipoprotein cholesterol (LDL-C) particles. This is believed to be a key factor in promoting atherosclerosis in these patients. There is ample evidence that aggressive statin therapy reduces cardiovascular end points in patients with DM in both primary and secondary prevention studies. In all persons with DM, current treatment guidelines recommend reduction of LDLC to less than 100 mg/dL, regardless of baseline lipid levels. In very high risk patients with DM and coronary heart disease lowering of LDL-C to less than 70 mg/dL may provide even greater benefits. Treatment for hypertriglyceridaemia is recommended only if TG levels is very high (>500 mg/dL).
- Full text:140-Article Text-1703-1-10-20141129.pdf
